NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 309 filers reported holding NOVOCURE LTD in Q1 2022. The put-call ratio across all filers is 1.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,905 | -31.0% | 45,900 | 0.0% | 0.02% | -35.7% |
| Q1 2023 | $2,760 | -18.0% | 45,900 | 0.0% | 0.03% | -26.3% |
| Q4 2022 | $3,367 | -99.9% | 45,900 | -11.4% | 0.04% | -7.3% |
| Q3 2022 | $3,936,000 | +1.3% | 51,800 | -7.3% | 0.04% | +13.9% |
| Q2 2022 | $3,885,000 | -27.7% | 55,900 | -13.9% | 0.04% | 0.0% |
| Q1 2022 | $5,377,000 | +4.9% | 64,900 | -5.0% | 0.04% | +20.0% |
| Q4 2021 | $5,128,000 | -35.4% | 68,300 | 0.0% | 0.03% | -38.8% |
| Q3 2021 | $7,934,000 | -37.3% | 68,300 | +1.0% | 0.05% | -50.0% |
| Q2 2021 | $12,644,000 | – | 67,600 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |